Table 2.
The prevalence of metastases according to patient characteristics and risk-groups
| Total | Lymph node metastases | Bone metastases | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| EAU risk group | ||||||
| Unfavorable intermediate risk | 123 | 32 | 6 | 5 | 1 | 0.8 |
| High-risk | 267 | 68 | 46 | 17 | 28 | 10 |
| Total | 390 | 100 | 52 | 13 | 29 | 7 |
| ISUP grade | ||||||
| 1 | 5 | 1 | 0 | 0 | 0 | 0 |
| 2 | 17 | 4 | 1 | 5 | 0 | 0 |
| 3 | 143 | 37 | 10 | 7 | 2 | 1 |
| 4 | 106 | 27 | 10 | 9 | 6 | 6 |
| 5 | 110 | 28 | 25 | 23 | 16 | 15 |
| Missing | 9 | 2 | 6 | 67 | 5 | 56 |
| Clinical T stage | ||||||
| 1 | 120 | 31 | 7 | 6 | 2 | 2 |
| 2(a+b) | 140 | 36 | 11 | 8 | 4 | 3 |
| 2c | 7 | 2 | 1 | 14 | 1 | 14 |
| 3 | 66 | 17 | 20 | 30 | 14 | 23 |
| 4 | 10 | 3 | 6 | 60 | 2 | 20 |
| Missing | 47 | 12 | 7 | 15 | 6 | 13 |
| Radiological T stage | ||||||
| 1 | 4 | 1 | 0 | 0 | 0 | 0 |
| 2 | 168 | 43 | 9 | 5 | 0 | 0 |
| 3a | 120 | 31 | 10 | 8 | 7 | 6 |
| 3b | 67 | 17 | 14 | 21 | 8 | 12 |
| 4 | 30 | 8 | 19 | 63 | 14 | 47 |
| Missing | 1 | 0 | 0 | 0 | 0 | 0 |